Home › Research › Mild cognitive impairment
Biomarkers for dementia and mild cognitive impairment in Parkinson's disease
Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jiménez-Urbieta H, Rodriguez-Oroz MC.. Movement disorders : official journal of the Movement Disorder Society, 2016-05-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well-established risk factor for the development of dementia. However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin-like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of distinct deficits with a distinct risk of dementia in subgroups of patients. Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This review of 25 years of studies on Parkinson's disease reports that no biomarker for dementia or mild cognitive impairment in Parkinson's disease has yet been validated, though several features might be indicative. It is a review of biomarker candidates and does not show that any treatment, cure, or prevention works.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Delgado-Alvarado, M., Gago, B., Navalpotro-Gomez, I., Jiménez-Urbieta, H., & Rodriguez-Oroz, M. C. (2016). Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. https://doi.org/10.1002/mds.26662
Vancouver
Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jiménez-Urbieta H, Rodriguez-Oroz MC. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2016. doi:10.1002/mds.26662. PMID: 27193487.
BibTeX
@article{delgadoalvarado2016-27193487,
author = {Delgado-Alvarado, M. and Gago, B. and Navalpotro-Gomez, I. and Jiménez-Urbieta, H. and Rodriguez-Oroz, M. C.},
title = {{Biomarkers for dementia and mild cognitive impairment in Parkinson's disease}},
journal = {Movement disorders : official journal of the Movement Disorder Society},
year = {2016},
doi = {10.1002/mds.26662},
pmid = {27193487},
url = {https://doi.org/10.1002/mds.26662}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Because it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions.
- In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process.
- Longitudinal studies combining the existing techniques and new approaches are needed to identify patients at higher risk of dementia. © 2016 International Parkinson and Movement Disorder Society.
Why it matters
This review of 25 years of studies on Parkinson's disease reports that no biomarker for dementia or mild cognitive impairment in Parkinson's disease has yet been validated, though several features might be indicative. It is a review of biomarker candidates and does not show that any treatment, cure, or prevention works.
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 53/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Movement disorders : official journal of the Movement Disorder Society) |
| Journal's citation record | 3 / 4 | Movement Disorders: journal h-index 281 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 157 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.1 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 4 / 6 | Cited 11.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 40 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author María Rodríguez‐Oroz: h-index 66 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad de Navarra: institution h-index 477 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27193487) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/mds.26662
- PubMed: 27193487
- Original source →
- Free full text: Communities in ADDI (Universidad del Pais Vasco) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 35.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Mild cognitive impairment from nearby years
Also tagged “mini-mental”
840 studies in the library carry the topic tag “mini-mental”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.